Should stem cell therapy be used in DLBCL?

By: Lymphoma Hub

Go here to read the rest:
Should stem cell therapy be used in DLBCL? - Video

Recommendation and review posted by simmons

Arthritic shoulders; Len discusses his results 9 months after stem cell therapy by Dr Harry Adelson
Arthritic shoulders; Len discusses his results 9 months after stem cell therapy by Dr Harry Adelson http://www.docereclinics.com.

By: Harry Adelson, N.D.

Go here to read the rest:
Arthritic shoulders; Len discusses his results 9 months after stem cell therapy by Dr Harry Adelson - Video

Recommendation and review posted by simmons

The Philippines is the biggest market for the popular, if highly controversial, alternative treatment in Germany called fresh-cell therapy (FCT). Fresh cells derived from the fetus of an unborn lamb are injected into patients, and are said to cure a large number of illnesses.

Despite the high cost of the treatment, wealthy Filipinos are undeterred, and typically arrive in droves in a sleepy town outside Frankfurt, their hopes of being cured or rejuvenated pinned on the life of every donor sheep.

Given its renown, its no surprise that questions about the efficacy and safety of FCT has been the subject of discussions among health professionals. There have also been rumors of deaths after FCT.

The proponents of FCT in Germany, however, claim that all talk about patient deaths and questionable safety standards are unfounded, and an uncouth effort to discredit FCT so that the same medical professionals here could promote stem-cell therapy, which is allowed in the country. They deny the rumors of deaths and challenge their accusers to show proof. They also maintain that FCT is a decades-old, legitimate and safe naturopathic treatment.

Theres also a rivalry in Edenkoben between the famous clinic Villa Medica and the breakaway practice of Dr. Robert Janson-Mller, who used to work at the same clinic.

Dr. Mller now administers FCT in a hotel, which doubles as his clinic. This gave rise to talks questioning the standards of a practice that is done in a hotel, not a hospital. Some accounts also say that there have been Filipino patients fooled into believing they were bound for Villa Medica, only to find themselves in Dr. Mullers hotel.

Inquirer Lifestyle visits the two rival clinics in Germany, and we experience firsthand what FCT is all about.

Follow Us

Recent Stories:

Tags: Dr. Robert Janson-Mller , Frankfurt , fresh cell therapy , Stem Cell Therapy , Villa Medica

Link:
The furor over fresh-cell therapy (which is NOT stem cell therapy)

Recommendation and review posted by simmons

FAIRMONT - Cancer can change everything about your life: your schedule, your finances, your activities, your friends, your faith, your attitude and, of course, your health.

When diagnosed with multiple myeloma - pronounced my-low-muh - a person is facing a life sentence with the disease. There is no cure. This cancer invades the bone marrow, affecting production of red cells, white cells and stem cells.

"More specifically, it is an uncontrolled growth of plasma cells, which attack and destroy bone," reads the brochure for Fairmont MN Area Multiple Myeloma Support Group.

Darlene Roebbeke reads from Guideposts to her husband Darrell at their home in Fairmont. Their faith in God and a strong support network have helped them persevere through Darrells diagnosis with multiple myeloma.

Leading the meetings, held every other month at Mayo Clinic Health System's hospital classroom in Fairmont, is Joyce Schultz of Ceylon, diagnosed with myeloma July 2008.

For several years, Schultz suffered from back pain, but then severe fatigue set in.

"I started getting so tired, I felt like there was definitely something wrong," she said.

Tests showed she had high levels of calcium in her blood - a signature trait of multiple myeloma.

"God bless the doctor who found it, because he didn't even let me go home that day. He sent me straight to Rochester," Schultz said.

By the time she arrived, she couldn't remember the names of close family members. Further testing provided the culprit - myeloma, a rare cancer that is frequently confused with its sound-alike, melanoma.

More:
Couple wages tough fight

Recommendation and review posted by Bethany Smith

Automatic isolation of antigen-specific T cells for adoptive T cell therapy
CD4+ and CD8+ T cells stimulated in vitro with a specific antigen can be magnetically labeled with the CliniMACS Cytokine Capture System (IFN-gamma). In com...

By: Miltenyi Biotec

View post:
Automatic isolation of antigen-specific T cells for adoptive T cell therapy - Video

Recommendation and review posted by Bethany Smith

EDENKOBEN, a postcard-pretty town an hours drive south of Frankfurt, offers picturesque scenes of vineyards

Its not only about adding years to life, but adding life to years.

This in essence sums up the philosophy behind Dr. Robert Janson-Mllers practice as a general practitioner in Munich and as a specialist (one of a handful) in live cell therapy in Edenkoben, a picturesque, grape-producing town one hour south of Frankfurt.

A growing number of Asians, including Filipinos suffering from such ailments as diabetes, heart disease, degenerative disorders of the joints and spinal column, multiple sclerosis, mild depression, burnout, migraine and even impotence, are braving the 14-hour flight to Germany to avail themselves of the therapy pioneered in the 30s by Swiss doctor Paul Niehans.

Live cell therapy, which is an organ-specific approach, involves harvesting fresh cells from sheep embryo and injecting them directly (intramuscular) on the patients buttocks.

Not a few parents also swear by the therapys beneficial effects on their children with mild autism, attention deficit and hyperactivity disorder (ADHD) and Downs syndrome.

DR. ROBERT Janson-Mller and his team composed of Joesoef Agoes, head nurse Simone Huethere, Dr.Wolgang Janson-Mller, assistant nurse Debbie Lehmann and Joey Santos

Better functions

During our coverage, for instance, we came across an Indonesian couple with an 11-year-old son with ADHD and mild autism. After trying all sorts of treatments to improve their sons focus and EQ, including a daily dose of the drug Concerta, the couple learned about live cell therapy from another parent with an autistic son.

Before live cell therapy, he was mostly limited to one-word sentences, said the dad of his son. And when he talked to people, he lacked eye contact. Now, I could teach him to form complete thoughts and sentences.

View post:
Live cell therapywhy its not about healing and performing miracles

Recommendation and review posted by Bethany Smith

EMIL Sison, Davao resident and Villa Medica patient. PHOTO BY CHECHE MORAL

At about this time last year, Emil Sison was hobbling around with the aid of a cane. His speech was so slurred that he was embarrassed to speak to people.

When he had to pay for something, hed feel the storekeepers exasperation as his shaky hands struggled to grip the bills from his wallet.

Sison, 66, was diagnosed with Parkinsons disease two years ago, a new blow for the retired Davao construction company owner who had already suffered from two heart attacks prior.

This time, Sisons new condition had symptoms so enfeebling that they threatened his quality of life, unacceptable for a man who refuses to slow down and resign himself to his bed as he awaits his end.

VILLA Medica managing director Bobby Chia with Miss Universe and actress Gloria Diaz and Villa Medica Philippines country manager Suzette Lopez in Edenkoben. PHOTO BY CHECHE MORAL

When we met him last month at the Villa Medica hospital in Edenkoben, Germany, a quiet little town surrounded by forests and vineyards an hour-and-a-half-long drive from Frankfurt, it was hard to imagine the robust man as he described himself from the year before, when he first received fresh-cell therapy (FCT). He came down from his room sans walking stick, his speech was clear, and he showed us that only two of his fingers remained slightly shaky.

I talked to another patient today, and he noted that it was my second time here, he said. And I said, I wouldnt be here again if its not good Last year, I thought tama na, malayo at mahal, kaya na. But when I felt new symptoms of the same disease, I thought, delikado. Ayokong maging bedridden. Ayokong maghintay na lang ng katapusan. (Thats enough, I thought. The treatment is far and expensive But I didnt want to be bedridden and just wait for my end.)

Like many Filipinos who may have heard of this unorthodox alternative treatment in Germany, Sison had doubts about FCTs efficacy, even as he had agreed to travel across the world and pay good money for the treatment.

Preventive, regenerative

Read the original post:
Filipinos make up biggest clientele of German fresh-cell therapy center

Recommendation and review posted by Bethany Smith

Researchers have found a connection between short-term memory lapses, such as losing your keys, and the dopamine D2 receptor gene (DRD2).

Psychologists from the University of Bonn report that people who have a certain variant of this gene are more easily distracted and experience a higher incidence of lapses due to a lack of attention.

Most of us are familiar with such everyday lapses, such as walking into a room and forgetting why you went there or forgetting the name of the person you are speaking with on the phone.

Such short-term memory lapses are very common, but some people experience them particularly often, said Dr. Martin Reuter from the Department for Differential and Biological Psychology at the University of Bonn.

In previous experiments, researchers discovered indications that the DRD2 plays a part in forgetfulness. The gene has an essential function in signal transmission within the frontal lobes.

This structure can be compared to a director coordinating the brain like an orchestra, said Dr. Sebastian Markett, principal author of the new study.

The DRD2 gene acts as the conductors baton, because it plays a part in dopamine transmission in the brain, he explained. If the baton skips a beat, the orchestra gets confused.

For their study, the researchers tested 500 people by taking a saliva sample and examining the DRD2 gene in each. All humans carry the DRD2 gene, which comes in two variants that are distinguished by only one letter within the genetic code. The one variant has C (cytosine), which is displaced by T (thymine) in the other.

According to the research teams analyses, about a quarter of those tested had the DRD2 gene with the cytosine nucleobase, while three quarters were the genotype with at least one thymine base.

The scientists then set out to discover if this difference in the genetic code had an effect on everyday behavior.

Read the original here:
Gene Variant Can Contribute to Forgetfulness

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise NEW YORK, NY (March 21, 2014) Researchers at Columbia University Medical Center (CUMC) have devised a new system for classifying periodontal disease based on the genetic signature of affected tissue, rather than on clinical signs and symptoms. The new classification system, the first of its kind, may allow for earlier detection and more individualized treatment of severe periodontitis, before loss of teeth and supportive bone occurs. The findings were published recently in the online edition of the Journal of Dental Research.

Currently, periodontal disease is classified as either chronic or aggressive, based on clinical signs and symptoms, such as severity of gum swelling and extent of bone loss. However, there is much overlap between the two classes, said study leader Panos N. Papapanou, DDS, PhD, professor and chair of oral and diagnostic sciences at the College of Dental Medicine at CUMC. Many patients with severe symptoms can be effectively treated, while others with seemingly less severe infection may continue to lose support around their teeth even after therapy. Basically, we dont know whether a periodontal infection is truly aggressive until severe, irreversible damage has occurred.

Looking for a better way to classify periodontitis, Dr. Papapanou turned to cancer as a model. In recent years, cancer biologists have found that, in some cancers, clues to a tumors aggressiveness and responsiveness to treatment can be found in its genetic signature. To determine if similar patterns could be found in periodontal disease, the CUMC team performed genome-wide expression analyses of diseased gingival (gum) tissue taken from 120 patients with either chronic or aggressive periodontitis. The test group included both males and females ranging in age from 11 to 76 years.

The researchers found that, based on their gene expression signatures, the patients fell into two distinct clusters. The clusters did not align with the currently accepted periodontitis classification, said Dr. Papapanou. However, the two clusters did differ with respect to the extent and severity of periodontitis, with significantly more serious disease in Cluster 2. The study also found higher levels of infection by known oral pathogens, as well as a higher percentage of males, in Cluster 2 than in Cluster 1, in keeping with the well-established observation that severe periodontitis is more common in men than in women.

Our data suggest that molecular profiling of gingival tissues can indeed form the basis for the development of an alternative, pathobiology-based classification of periodontitis that correlates well with the clinical presentation of the disease, said Dr. Papapanou.

The researchers next goal is to conduct a prospective study to validate the new classification systems ability to predict disease outcome. The team also hopes to find simple surrogate biomarkers for the two clusters, as it would be impractical to perform genome-wide testing on every patient.

The new system could offer huge advantages for classifying people with different types of periodontitis. If a patient is found to be highly susceptible to severe periodontitis, we would be justified in using aggressive therapies, even though that person may have subclinical disease, said Dr. Papapanou. Now, we wait years to make this determination, and by then, significant damage to the tooth-supporting structures may have occurred.

The paper is titled, Gingival Tissue Transcriptomes Identify Distinct Periodontitis Phenotypes. The other contributors are M. Kebschull (CUMC), R.T. Demmer (CUMC), B. Grn (University of Linz, Linz, Austria), P. Guarnieri (CUMC), and P. Pavlidis (University of British Columbia, Vancouver, BC, Canada).

See the article here:
Gene Expression Signature Reveals New Way to Classify Gum Disease

Recommendation and review posted by Bethany Smith

Daniel Estulin: The Coming Age of Human Deconstruction
Michael Cross, author of the "Freedom from Conscience" series and host of "Unlock the Door" radio interviews Daniel Estulin, author of "TransEvolution: The C...

By: Michael Cross

Here is the original post:
Daniel Estulin: The Coming Age of Human Deconstruction - Video

Recommendation and review posted by Bethany Smith

Genetic Engineering - The Interview

By: TavongaNyokaSchool

See the original post here:
Genetic Engineering - The Interview - Video

Recommendation and review posted by Bethany Smith

A farmers' body affiliated to the CPI(M) on Saturday criticised the decision of the Genetic Engineering Approval Committee (GEAC) to revalidate the field trials for 10 varieties of Genetically Modified (GM) food crops and sought the Election Commission's intervention to "stall the undemocratic move."

"This decision is a bonanza given on the eve of the elections to the Indian and MNC agri businesses and reeks of corrupt intentions. It is undemocratic and violation of Election Commission guidelines," the All India Kisan Sabha (AIKS) said. It said the decision was taken in a "hasty manner" despite serious concerns expressed by wide sections.

"AIKS requests the Election Commission to intervene to stall this undemocratic move bypassing Parliament and aimed at aiding profiteering by big agri businesses," it said. "The hasty and non-transparent decision of the environment ministry on the eve of announcement of Lok Sabha elections to allow field trials despite the absence of a stringent mechanism to ensure bio-safety as well as a strong regulatory body opened the floodgates for field trials and set in motion these fast-paced developments," it said.

The GEAC, a statutory body for approving GM crops, had yesterday decided to revalidated proposals for wider field trials for 10 GM crops including wheat and rice. Over 70 new proposals including of many food crops will also be examined by GEAC in April.

AIKS said the applications for revalidation were made by companies whose permits had lapsed as they were opposed by states.

The decision will allow Mahyco, BASF India and Monsanto India to go ahead with wider or phase-II field trials for these genetically modified crops.

Originally posted here:
Govt nod for GM crop field trials violates EC guidelines, says farmers' body

Recommendation and review posted by Bethany Smith

Genetics Lesson 1: Problem Set with ANSWERS 🙂
This video screencast was created with Doceri on an iPad. Doceri is free in the iTunes app store. Learn more at http://www.doceri.com.

By: Aubrie Holman

More:
Genetics Lesson 1: Problem Set with ANSWERS 🙂 - Video

Recommendation and review posted by Bethany Smith

Bioethicist Julian Savulescu Andrew Denton - Drugs, Genetics, Eugenics
Welcome to Oxford University where Professor Julian Savulescu is a man who favours more drugs than sport, who thinks cloning is cool and who says that if the...

By: AustralianRealist

Excerpt from:
Bioethicist Julian Savulescu & Andrew Denton - Drugs, Genetics, Eugenics - Video

Recommendation and review posted by Bethany Smith

Cancer Gene Therapy Market
Cancer Gene Therapy Market http://www.reportsnreports.com/reports/276997-cancer-gene-therapy-market-analysis.html . A major part of the cancer gene therapy p...

By: Robert Dj

View post:
Cancer Gene Therapy Market - Video

Recommendation and review posted by Bethany Smith

NWCS biology gene therapy
A breif overview of the basic process of bene therapy.

By: Rachel Leo

Originally posted here:
NWCS biology gene therapy - Video

Recommendation and review posted by Bethany Smith

Senator Bonacic discusses designated State Funding for Spinal Cord injury Research
March 18, 2014 - Senator Bonacic discusses designated State Funding for Spinal Cord injury Research.

By: NYSenate

See the article here:
Senator Bonacic discusses designated State Funding for Spinal Cord injury Research - Video

Recommendation and review posted by sam

Grant Korgan - Spinal Cord Injury to Hydrofoiling
My name is Grant Korgan. On March 5th 2010, I burst fractured my L1 vertebra on the snow in the Sierra back country I sustained a Spinal Cord Injury and inst...

By: thekorgmovement

See the article here:
Grant Korgan - Spinal Cord Injury to Hydrofoiling - Video

Recommendation and review posted by sam

Riluzole as treatment for Spinal Cord Injury
Mechanism of action of Riluzole in the treatment of traumatic spinal cord injury. Animation produced for Dr. Michael G. Fehlings at Toronto Western Research ...

By: Synapse Visuals

Go here to read the rest:
Riluzole as treatment for Spinal Cord Injury - Video

Recommendation and review posted by sam

PUBLIC RELEASE DATE:

20-Mar-2014

Contact: Matthew Inlay minlay@uci.edu 949-824-8226 University of California - Irvine

Irvine, Calif., March 20, 2014 Hematopoietic stem cells are now routinely used to treat patients with cancers and other disorders of the blood and immune systems, but researchers knew little about the progenitor cells that give rise to them during embryonic development.

In a study published April 8 in Stem Cell Reports, Matthew Inlay of the Sue & Bill Gross Stem Cell Research Center and Stanford University colleagues created novel cell assays that identified the earliest arising HSC precursors based on their ability to generate all major blood cell types (red blood cells, platelets and immune cells).

This discovery of very early differentiating blood cells, Inlay said, may be very beneficial for the creation of HSC lines for clinical treatments.

"The hope is that by defining a set of markers that will allow us to make purer, cleaner populations of these precursor cells, we'll be able to reveal the key molecular events that lead to the emergence of the first HSCs in development. This could give us a step-by-step guide for creating these cells in a dish from pluripotent stem cell lines" added Inlay, who is an assistant professor of molecular biology & biochemistry at UC Irvine and conducted the study while a postdoctoral researcher in the Irving Weissman lab in the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University.

###

The work was performed in collaboration with Thomas Serwold, now an assistant professor in the Joslin Diabetes Center at Harvard Medical School.

The research reported in this article was supported by the National Institutes of Health (grants 5 T32 AI07290, R01HL058770, R01CA86085 and U01HL09999), the California Institute for Stem Cell Research (grants T1-00001, RT2-02060 to I.L.W.), the Harvard Stem Cell Institute, the Siebel Stem Cell Institute, the Thomas and Stacey Siebel Foundation, and the Virginia and D.K. Ludwig Fund for Cancer Research.

Original post:
Stem cell study finds source of earliest blood cells during development

Recommendation and review posted by simmons

Miami (PRWEB) March 21, 2014

Stem Cell Training, Inc., a division of the Global Stem Cells Group, and Bioheart, Inc. have announced the successful completion of their first joint stem cell training course held in the U.S.

Titled Adipose Derived Harvesting, Isolation and Re-integration Training Course, for the advancement of stem cell procedures, the two companies hosted 14 students in Miami for the training, conducted by Bioheart CSO Kristin Comella.

The two-day, hands-on intensive training course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose (fat) tissue and bone marrow. The objective of the training is to bridge the gap between bench science in the laboratory and the doctors office by teaching effective in office regenerative medicine techniques.

Comella, Chief Scientific Officer for Bioheart, has more than 15 years experience in cell culturing and developing stem cell therapies for degenerative diseases, and experience in corporate entities, with expertise in regenerative medicine, training and education, research, product development and senior management.

The two companies will conduct 12 stem cell training courses in the U.S. during 2014. For more information, visit the Stem Cell Training, Inc. website, email info(at)stemcelltraining(dot)net, or call 305-224-1858.

About Stem Cell Training, Inc.:

Stem Cell Training, Inc. is a multi-dimensional company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

The companys training courses are designed to make the best use of stem cell technology available to treat various diseases in a manner that is accessible to everyone. Stem Cell Training, Inc.s mission is to introduce the promising world of cellular medicine to everyone who can benefit from its application, and to provide high quality, effective and efficient training that complies with the highest medical standards to physicians worldwide.

About the Global Stem Cells Group:

Excerpt from:
Stem Cell Training, Inc. and Bioheart, Inc. Complete First U.S.-based Stem Cell Training Course

Recommendation and review posted by simmons

Poway, California (PRWEB) March 21, 2014

Ruby, a 10 year old Border Collie mix from Breckenridge, Colorado, has found relief from the pain of arthritis with stem cell therapy by Vet-Stem, Inc. Rubys owners came to Jamie Gaynor, DVM at Frisco Animal Hospital for a second opinion after being told Ruby would need a total hip replacement to relieve her constant pain and discomfort. Her quality of life had diminished so rapidly they feared losing her.

Dr. Gaynor began performing stem cell therapy by Vet-Stem for pets in 2006, in Colorado Springs. Paralleling his specialties in pain management, he has now helped well over one hundred pets in the state of Colorado, and ones that traveled just to have his expertise. His credentials and experience made Dr. Gaynor the perfect fit for helping Rubys worsening bilateral hip arthritis despite aggressive drug therapy. Ruby would become Dr. Gaynors first stem cell therapy case at Frisco Animal Hospital; Summit Countys first and oldest animal hospital.

Ruby was in constant pain and discomfort. She had to be carried up stairs and could not go on car rides; her second favorite thing to do. Her quality of life was diminishing rapidly, and we thought we were losing her, explained Rubys owners.

Rubys stem cell procedure consisted of a small fatty tissue collection, which was sent overnight to Vet-Stems lab in California for processing. Once Rubys fat was processed, and stem cells were extracted, fresh doses of her stem cells were sent overnight back to Dr. Gaynor in injectable doses. Within 48hrs of collecting a fat sample from Ruby, Dr. Gaynor was able to inject stem cells into each of her arthritic, painful hips, making Ruby his first stem cell therapy case in Summit County.

Dr. Gaynor and Rubys owners were both pleased with the successful outcome of the procedure, and had the opportunity to share during her 30 day recheck. Ruby is back! She has regained her playfulness, sassy, bossy, collie attitude. She has resumed going for car rides and can stand up and stabilize herself. She jumps out of the car without hesitation. She ascends and descends the stairs like she used to, her owners remarked about Rubys physical performance.

Her entire disposition and expressions are so animated and relaxed. I forgot how she used to smile, hold her ears up, and have endless energy. She is definitely out of pain, and her mobility is at 80%! The best part is, that she continues to heal and get stronger each week. This procedure is hands down the most effective, least traumatic therapy available, especially for the older dog, Rubys owners expressed.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

View original post here:
Stem Cell Therapy for Pets in Summit County Colorado Proves to Be a Success for Local Dog Suffering from Pain

Recommendation and review posted by simmons

In India, stem cell biz may touch $8 b by 2015

Mumbai, March 21:

Stem cells are set to be a major branch of medical treatment, says Cipla Chairman YK Hamied. Regenerative medicine, or cell therapy, is a rapidly emerging area of biomedical research and would be an ideal supplement for existing medical treatments, he added.

Cell therapy refers to treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury.

We have a research unit in Malaysia that is conducting research on stem cells, Hamied said while speaking about Stempeutics Research with which it has an alliance. The Manipal Group-promoted Stempeutics is developing stem cell-based medicinal products with facilities in Kuala Lumpur (Malaysia) and Bangalore.

We are partners in the Bangalore company, he said. The enormous potential of stem cells in the treatment of chronic and several incurable diseases is boosting the overall stem cells therapy market, he added.

Poised to reach an estimated $88.3 billion by 2015, the global stem cells market has been growing at a compounded annual growth rate of 14.8 per cent, driven by the increasing demand of stem cell therapy.

In India, the stem cell business is expected to touch $8 billion (48,880 crore today) by 2015. With three phase II clinical trials in progress in India for critical limb Ischemia (meaning restriction in blood supply to tissues), osteoarthritis and liver cirrhosis Stempeutics aims to bring the first product into the Indian and Malaysian markets by 2015.

Under the alliance, Cipla has invested over 50 crore in Stempeutics, with a focus on research of stem cell-based products, and has done something similar in China, where it has streamlined its investments towards its core business. The drug-maker recently exited a significant part of its investment in its Chinese partner Desano Holdings.

Despite the lack of legislation and awareness, besides quality and ethical issues that have deterred growth of the stem cell therapy business in India, the country remains the top priority for the Mumbai-based drug-maker, the Cipla Chairman told Business Line.

See original here:
Cipla bets big on cell therapy

Recommendation and review posted by simmons

Miami (PRWEB) March 20, 2014

Joseph Purita, M.D. and Maritza Novas, R.N., M.S.N. of Global Stem Cells Group Inc., and Bioheart, Inc. Chief Scientific Officer Kristin Comella will be featured speakers at the 31st American Association of Orthopedic Medicine Annual Conference (AAOM) Conference and Scientific Seminar in Clearwater Beach, Florida April 9-12, 2014. Co-sponsored by the American Board of Quality Assurance and Utilization Review Physicians, Inc. (ABQAURP), the conference, titled Sports, Spine and Beyond: Latest Advances in Regenerative Orthopedic Medicine, will focus on the newest breakthroughs in the field of orthopedic medicine.

Purita, Novas and Comella will present the latest advances in stem cell therapies in sports medicine, regenerative orthopedic medicine and interventional pain medicine, including techniques for extracting stem cells from adipose tissue to use in patient treatments. Purita is a pioneer in the use of stem cells in orthopedics and founder of the Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida. Novas is a lead trainer and part of the research and development team for Stem Cell Training, a Global Stem Cells Group subsidiary.

Comella has more than 15 years experience in cell culturing and developing stem cell therapies for degenerative diseases and experience in corporate entities, with expertise in regenerative medicine, training and education, research, product development and senior management.

The conference will explore advances in other non-traditional treatments in sports and regenerative orthopedic medicine including manual medicine, nutrition, bioidentical hormone replacement therapy, musculoskeletal ultrasound and more. The goal of the AAOM Conference is to bring sports medicine physicians, PM&R specialists (physiatrists), family medicine physicians, orthopedic surgeons, neurologists and interventional pain physiciansincluding anesthesiologists and osteopathic pain physiciansthe latest state-of-the-art techniques and technologies to help treat their patients performance-related pain and injuries, overuse syndromes and chronic pain.

For more information on the 31st AAOM Annual Conference and Scientific Seminar, visit the AAOM website.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

To learn more about Global Stem Cells Group, Inc.s companies and for investor information, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

See the article here:
Joseph Purita, M.D. and Maritza Novas, R.N., M.S.N. of Global Stem Cells Group, Inc. and Bioheart CSO Kristin Comella ...

Recommendation and review posted by Bethany Smith

Mar 20, 2014 Levels of the regulatory protein GtaC, tagged with green fluorescent protein, increase in the nucleus every six minutes. GtaC turns on genes that prepare cells to move. The image is a compilation of eight photos, taken at 3.5 minute intervals, showing GtaC's location in a single cell as it moves. Credit: Huaqing Cai

Johns Hopkins biologists have discovered that when biological signals hit cells in rhythmic waves, the magnitude of the cells' response can depend on the number of signaling cyclesnot their strength or duration. Because such so-called "oscillating signaling cycles" are common in many biological systems, the scientists expect their findings in single-celled organisms to help explain the molecular workings of phenomena such as tissue and organ formation and fundamental forms of learning.

In a report to be published online in the journal Science on March 21, the investigators say their experiments in amoebae show how repeated pulses of a signal cause short bursts of specific gene activity, the products of which linger and build with each new pulse. The cumulative amount of these gene products ultimately affects changes in cell fate.

"The mechanism we discovered here illustrates how a single cell can keep track of the number of times it has received a signal," says Peter Devreotes, Ph.D., professor and director of the Department of Cell Biology. "In most signaling systems, the cellular response depends on the strength or duration of the signal. This system allows the cells to count."

The Devreotes team says they figured out this signaling system in the amoeba Dictyostelium discoideum, a single-celled organism that can cluster to form a multi-celled structure that helps it survive when resources are scarce. At the heart of this process, they say, is a communication molecule called cAMP, a chemical released by starving cells in periodic spurtsevery six minutesthat is sensed by other cells nearby. The signal triggers a series of steps needed for the cells to join together and form specialized types of cells within the group makeup.

Devreotes says, "We have known since the 1970s that the cAMP signals achieve their best effect when they arrive every six minutesnot more and not lessbut we had no idea why."

To find out, the Johns Hopkins team focused on the behavior of a regulatory protein called GtaC, which is similar to the human GATA genes known to control stem cell fate in many tissues. Amoebae that lack GtaC can't activate the genes that enable the initially similar cells to cluster and to become the specialized cell types of the multicellular structure.

When the researchers attached GtaC to a protein that glows green, they saw that it entered the amoeba cell nucleus, left the nucleus and then entered again at a pace like the six-minute pulses of cAMP. If the researchers gave the cells a continuous supply of cAMP, GtaC would leave the nucleus after a brief lag and remain outside of it for as long as cAMP was present. When they removed cAMP, GtaC would re-enter the nucleus.

The researchers then engineered GtaC to stay put in the nucleus and found that the cells began to come together and specialize prematurely. However, in cells that lacked cAMP, the team found that these processes were not turned on even with GtaC in the nucleus.

To better understand the role of GtaC, the researchers used a protein that can glow to show when GtaC turned on a particular gene. What they found was another rhythmic, six-minute pattern of activity: The glowing spots indicating gene activity peaked in intensity approximately every six minutes and lagged about three minutes behind the peak of GtaC accumulation in the nucleus. According to Devreotes, this three-minute lag is likely due to the time it takes for the gene to be turned on and seen.

Follow this link:
Cellular 'counting' of rhythmic signals synchronizes changes in cell fate

Recommendation and review posted by Bethany Smith